Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
3.6 million Medicare enrollees may become eligible for Wegovy, an anti-obesity drug, with potential $3B annual cost.
3.6 million Medicare enrollees may become eligible for coverage of Wegovy, an anti-obesity drug, according to a KFF analysis.
The FDA approved Wegovy for reducing cardiovascular disease risk in overweight or obese adults without diabetes.
However, Medicare's budget may be strained as it could cost nearly $3 billion annually and contribute to higher Part D premiums for all beneficiaries.
8 Articles
3,6 millones de afiliados a Medicare pueden ser elegibles para Wegovy, un medicamento contra la obesidad, con un costo anual potencial de $3 mil millones.